Biopower in Japan Market 2017–By Identifying the Key Market Segments Poised for Strong Growth in Future

Biopower in Japan Industry by Manufacturers, Production and Applications Research Report Forecast to 2030

PUNE, INDIA, August 31, 2017 /EINPresswire.com/ — Summary
"Biopower in Japan, Market Outlook to 2030, Update 2017 – Capacity, Generation, Levelized Cost of Energy (LCOE), Investment Trends, Regulations and Company Profiles", is the latest report from the industry analysis specialists that offer comprehensive information and understanding of the Biopower market in Japan.

The report provides an in-depth analysis on global renewable power market and global Biopower market with forecasts up to 2030. The report analyzes the power market scenario in Japan (includes conventional Hydro, nuclear and renewable energy sources) and provides future outlook with forecasts up to 2030. The research details renewable power market outlook in the country (includes Wind, small hydro, biopower and renewable) and provides forecasts up to 2030. The report highlights installed capacity and power generation trends from 2006 to 2030 in Japan Biopower market. A detailed coverage of energy policy framework governing the market with specific policies pertaining to Biopower market development is provided in the report. The research also provides company snapshots of some of the major market participants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2030164-biopower-in-japan-market-outlook-to-2030-update-2017-capacity-generation

Scope
The report analyses global renewable power market, global biopower (Biomass and Biogas) market, Japan power market, Japan renewable power market and Japan biopower market. The scope of the research includes –
– A brief introduction on global carbon emissions and global primary energy consumption.
– An overview on global renewable power market, highlighting installed capacity trends, generation trends and installed capacity split by various renewable power sources. The information is covered for the historical period 2006-2016 (unless specified) and forecast period 2017-2030.
– Renewable power sources include wind (both onshore and offshore), solar photovoltaic (PV), concentrated solar power (CSP), small hydropower (SHP), biomass, biogas and geothermal.
– Detailed overview of the global biopower market with installed capacity and generation trends, installed capacity and generation split by major biopower countries in 2016.
– Power market scenario in Japan and provides detailed market overview, installed capacity and power generation trends by various fuel types (includes thermal conventional, nuclear, large hydro and renewable energy sources) with forecasts up to 2030.
– An overview on Japan renewable power market, highlighting installed capacity trends (2006-2030), generation trends(2006-2030) and installed capacity split by various renewable power sources in 2016.
– Detailed overview of Japan biopower market with installed capacity and generation trends and major active and upcoming biopower projects.
– Deal analysis of Japan biopower market. Deals are analyzed on the basis of mergers, acquisitions, partnership, asset finance, debt offering, equity offering, private equity (PE) and venture capitalists (VC).
– Key policies and regulatory framework supporting the development of renewable power sources in general and biopower in particular.
– Company snapshots of some of the major market participants in the country.

Reasons to buy
– The report will enhance your decision making capability in a more rapid and time sensitive manner.
– Identify key growth and investment opportunities in Japan biopower market.
– Facilitate decision-making based on strong historic and forecast data for wind power market.
– Position yourself to gain the maximum advantage of the industry’s growth potential.
– Develop strategies based on the latest regulatory events.
– Identify key partners and business development avenues.
– Understand and respond to your competitors’ business structure, strategy and prospects.

Table of Content: Key Points

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Executive Summary 7
2.1 Global Carbon Emissions to Increase at a Lower rate During the Forecast Period 7
2.2 Technological Advancements and Government Support Driving Global Renewable Power Installations 7
2.3 Global Biopower Generation Expected to Reach Over 895 TWh by 2030 7
2.4 Thermal Power to remain as the Dominant Source in the Power Mix 9
2.5 Reforms in Regulatory Dynamics are required to boost the Growth of Renewable Sector 10
3 Introduction 11
3.1 Carbon Emissions, Global, 2001-2016 11
3.2 Primary Energy Consumption, Global, 2001-2030 13
3.3 Biopower Market, Technology Analysis 16
3.3.1 Biopower Market, Feedstock Conversion Processes 16
3.3.2 Biopower Market, Primary Energy Conversion and Recovery Technology 18
3.4 Report Guidance 21
4 Renewable Power Market, Global, 2006-2030 22
4.1 Renewable Power Market, Global, Overview 22
4.2 Renewable Power Market, Global, Installed Capacity, 2006-2030 23
4.2.1 Renewable Power Market, Global, Cumulative Installed Capacity by Source Type, 2006-2030 23
4.2.2 Renewable Power Market, Global, Cumulative Installed Capacity Split by Source Type, 2016 and 2030 25
4.2.3 Renewable Power Market, Global, Net Capacity Additions by Source Type, 2016-2030 27
4.2.4 Renewable Power Market, Global, Comparison by Cumulative Installed Capacity of Technology, 2016-2030 29
4.3 Renewable Power Market, Global, Power Generation, 2006-2030 31
4.3.1 Renewable Power Market, Global, Power Generation by Source Type, 2006-2030 31
4.3.2 Renewable Power Market, Global, Power Generation, Source Comparison Based on Power Generation, 2016-2030 33
4.4 Renewable Power Market, Global, LCOE Comparison of Power Generating Sources, 2014-2014 35
5 Biopower Market, Global, 2006-2030 38
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2030164-biopower-in-japan-market-outlook-to-2030-update-2017-capacity-generation

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Hydropower in Japan Market 2017 -Develop Market-Entry and Market Expansion Strategies

Hydropower in Japan Market 2017 – Identify Opportunities and Challenges

PUNE, INDIA, August 31, 2017 /EINPresswire.com/ — Summary
"Hydropower (Large, Small and Pumped Storage) in Japan, Market Outlook to 2030, Update 2017 – Capacity, Generation, Regulations and Company Profiles", is the latest report from the industry analysis specialists that offer comprehensive information and understanding of the hydropower market in Japan.

The report provides in depth analysis on global renewable power market and global hydropower market with forecasts up to 2030. The report analyzes the power market scenario in Japan (includes conventional thermal, nuclear, large hydro and renewable energy sources) and provides future outlook with forecasts up to 2030. The research details renewable power market outlook in the country (includes hydro, small hydro, biopower and solar PV) and provides forecasts up to 2030. The report highlights installed capacity and power generation trends from 2006 to 2030 in Japan hydropower market. A detailed coverage of renewable energy policy framework governing the market with specific policies pertaining to hydropower is provided in the report. The research also provides company snapshots of some of the major market participants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2030163-hydropower-large-small-and-pumped-storage-in-japan-market-outlook-to

Scope
The report analyses global renewable power market, global hydropower market, Japan power market, Japan renewable power market and Japan hydropower market. The scope of the research includes –
– A brief introduction on global carbon emissions and global primary energy consumption.
– An overview on global renewable power market, highlighting installed capacity trends, generation trends and installed capacity split by various renewable power sources. The information is covered for the historical period 2006-2016 (unless specified) and forecast period 2017-2030.
– Renewable power sources include wind (both onshore and offshore), solar photovoltaic (PV), concentrated solar power (CSP), small hydropower (SHP), biomass, biogas and geothermal.
– Detailed overview of the global hydropower market with installed capacity and generation trends, installed capacity split by major hydropower countries in 2016 and key owners information of various regions.
– Power market scenario in Japan and provides detailed market overview, installed capacity and power generation trends by various fuel types (includes thermal conventional, nuclear, large hydro and renewable energy sources) with forecasts up to 2030.
– An overview on Japan renewable power market, highlighting installed capacity trends (2006-2030), generation trends(2006-2030) and installed capacity split by various renewable power sources in 2016.
– Detailed overview of Japan hydropower market with installed capacity and generation trends and major active and upcoming hydro projects.
– Deal analysis of Japan hydropower market. Deals are analyzed on the basis of mergers, acquisitions, partnership, asset finance, debt offering, equity offering, private equity (PE) and venture capitalists (VC).
– Key policies and regulatory framework supporting the development of renewable power sources in general and hydropower in particular.
– Company snapshots of some of the major market participants in the country.

Reasons to buy
– The report will enhance your decision making capability in a more rapid and time sensitive manner.
– Identify key growth and investment opportunities in Japan hydropower market.
– Facilitate decision-making based on strong historic and forecast data for hydropower market.
– Position yourself to gain the maximum advantage of the industry’s growth potential.
– Develop strategies based on the latest regulatory events.
– Identify key partners and business development avenues.
– Understand and respond to your competitors’ business structure, strategy and prospects.

Table of Content: Key Points

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Executive Summary 7
2.1 Fall in OECD Countries’ Carbon Emission despite a Global Rise during 2010-2015 7
2.2 Technological Advancements and Government Support Driving Global Renewable Power Installations 7
2.3 Top 10 Countries Account for Over 70% of Hydropower Capacity 7
2.4 Thermal Power to remain as the Dominant Source in the Power Mix 8
2.5 Reforms in Regulatory Dynamics are required to boost the Growth of Renewable Sector 9
3 Introduction 10
3.1 Carbon Emissions, Global, 2001-2016 10
3.2 Primary Energy Consumption, Global, 2001-2025 12
3.3 Hydropower, Global, Technology Definition and Classification 15
3.4 Report Guidance 15
4 Renewable Power Market, Global, 2006-2030 16
4.1 Renewable Power Market, Global, Overview 16
4.2 Renewable Power Market, Global, Installed Capacity, 2006-2030 17
4.2.1 Renewable Power Market, Global, Cumulative Installed Capacity by Source Type, 2006-2030 17
4.2.2 Renewable Power Market, Global, Cumulative Installed Capacity Split by Source Type, 2016 and 2030 19
4.2.3 Renewable Power Market, Global, Net Capacity Additions by Source Type, 2016-2030 21
4.2.4 Renewable Power Market, Global, Comparison by Cumulative Installed Capacity of Technology, 2016-2030 23
4.3 Renewable Power Market, Global, Power Generation, 2006-2030 25
4.3.1 Renewable Power Market, Global, Power Generation by Source Type, 2006-2030 25
4.3.2 Renewable Power Market, Global, Power Generation, Source Comparison Based on Power Generation, 2016-2030 27
4.4 Renewable Power Market, Global, LCOE Comparison of Power Generating Sources, 2014-2014 29
5 Hydropower Market, Global, 2006-2030 33
5.1 Hydropower Market, Global, Overview 33
5.2 Hydropower Market, Global, Installed Capacity, 2006-2030 34
5.2.1 Hydropower Market, Global, Installed Capacity Share by Region, 2016 and 2030 36
5.2.2 Hydropower Market, Global, Installed Capacity Share by Country, 2016 and 2030 38
5.2.3 Hydropower Market, Global, Installed Capacity Share by Segment, 2016 and 2030 40
5.3 Hydropower Market, Global, Power Generation, 2006-2030 42
5.3.1 Hydropower Market, Global, Generation Share by Region, 2016 and 2030 44
5.3.2 Hydropower Market, Global, Generation Share by Country, 2016 and 2030 46
5.3.3 Hydropower Market, Global, Generation Share by Segment, 2016 and 2030 48
5.4 Hydropower Market, Global, Investment Trends, 2016-2020 50
6 Power Market, Japan, 2006-2030 52
6.1 Power Market, Japan, Overview 52
6.2 Power Market, Japan, Installed Capacity, 2006-2030 53
6.2.1 Power Market, Japan, Cumulative Installed Capacity by Fuel Type, 2006-2030 53
6.2.2 Power Market, Japan, Share in Cumulative Installed Capacity Split by Source Type, 2016 and 2030 56
6.2.3 Power Market, Japan, Net Capacity Additions by Fuel Type, 2016 and 2030 58
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2030163-hydropower-large-small-and-pumped-storage-in-japan-market-outlook-to

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Bakery & Cereals in Australia Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts To 2021

Bakery & Cereals in Australia Market Research Report 2017 Analysis and Forecast to 2021

PUNE, INDIA, August 31, 2017 /EINPresswire.com/ — Pune, India, 31st August 2017: WiseGuyReports announced addition of new report, titled “Top Growth Opportunities: Bakery & Cereals in Australia”.

Summary
Consumer and Market Insights "Top Growth Opportunities: Bakery & Cereals in Australia", provides an overview of the bakery and cereal market, analyzing market data, demographic consumption patterns within the category, and the key consumer trends driving consumption. The report highlights top growth opportunities for bakery & cereals market in Australia and outlines new product development that effectively targets the most pertinent consumer need states, and offers strategic recommendations to capitalize on evolving consumer landscapes.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2030160-top-growth-opportunities-bakery-cereals-in-australia

This report identifies the key demographic groups driving consumption, and what motivates their consumption. When combined with an in-depth study of market and category dynamics, readers are able to identify key opportunities, and what they need to do in order to target them. The report uses a unique method of quantifying consumer trends to highlight the degree of influence they have on consumption within the category. The report also identifies the most important trends within the market and shows whether beliefs over what influences consumer behavior within the category are accurate.

This report brings together consumer analysis and market data to provide actionable insight into the behavior of Australia's Bakery & Cereals consumers. This is based on unique consumer data, developed from extensive consumption surveys and consumer group tracking, which quantifies the influence of 20 consumption motivations in the Bakery & Cereals sector. Category, brand, and packaging dynamics are also examined. This allows product and marketing strategies to be better aligned with the leading trends in the market.

Scope
– The Australian Bakery & Cereals market saw a small decline in US$ between 2011 and 2016, due to the depreciation of the Australian Dollar. However, the growth is forecast to change to positive in the next five years between 2016 and 2021.
– Australia ranks among the biggest markets in the global Bakery & Cereals sector in terms of per capita consumption, concretely third in 2016, and expected to become the second largest by 2021
– Opportunities for premiumization in Bakery & Cereals have been limited over the past five years, but this situation is expected to improve between 2016 and 2021.
– Domestic Bakery & Cereals brands in Australia have outperformed international ones.

Reasons to buy
Get access to –
– Key consumer demographic groups driving consumption within the Australian market. The figures showcase the number of times consumers of specific ages and gender consume Bakery & Cereals, as well as identifying whether these demographic groups "over" consume in the category (i.e. they account for a higher proportion of occasions than the proportion of society they represent overall)
– A study of market value and volumes over 2011-2016 for Australia, supplemented with category, brand and packaging analysis that shows the current state of the market, and how it will evolve over the 2016-2021 period
– The degree of influence that the 20 key consumer trends identified by GlobalData have on Bakery & Cereals consumption volumes, with granular analysis on the extent that degree of influences varies between gender and age group
– Insight into the implications behind the data, and analysis of how the consumer needs will evolve in the short-to-medium term future
– Examples of international and Australia-specific product innovation targeting key consumer needs

Table of Content: Key Points

1. Introducing a top growth market for Bakery & Cereals
Top 10 global growth opportunities scores
Top global issues
Assessment against global strategic issues
Predicted future issues for the global sector
Reward and risk assessment
Opportunity score – overview
Consumer spending trends – peer group comparisons
Political, Economic, Social, and Technological: Analysis
Enablers and inhibitors of growth
Rewards and opportunities for growth
Summary of the market

2. Market insight – identifying the opportunities to move into
Market growth by category
Value growth of the market
Volume growth of the market
Level of premiumization by category
Category analysis – key factors driving change

3. Retail and distribution insight – key channels and retailers driving growth
Bakery & Cereals retail channel share
Key Retail Channel trends
Routes to market
Drivers of change in the sector

4. Company and brand insight – the competitive landscape defined
Category fragmentation
Company and brand strength
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2030160-top-growth-opportunities-bakery-cereals-in-australia

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Venous Thromboembolism Drug Forecast and Market Analysis to 2026

Venous Thromboembolism Therapeutics Development and Professional Review Analysis 2026

PUNE, INDIA, August 31, 2017 /EINPresswire.com/ — Pune, India, 31st August 2017: WiseGuyReports announced addition of new report, titled “PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026”.

Summary
Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual’s deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs. Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1930314-pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2026

Key Questions Answered
– The NOACs will see a significant increase in patient shares for the treatment of VTE and VTE primary prophylaxis against the established vitamin K antagonists and heparins. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the VTE market?
– The current late-stage VTE pipeline consists of betrixaban and Xarelto for thromboprophylaxis in acute medically ill patients, as well as first in class Factor XI inhibitor, IONIS-FXIRX and vitamin K antagonist, tecarfarin. Will the late-stage drugs make a significant impact on the VTE market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
– We have seen a significant increase in the VTE population, in terms of diagnosed incidence and recurrent attacks, as well as an increase in the prophylaxis population. How will epidemiological changes impact the growth of the future market?

Scope
– Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global VTE therapeutics market from 2016-2026.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Content: Key Points

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 9
2 Executive Summary 11
2.1 Sales for Venous Thromboembolism by Region, 2016-2026 12
2.2 VTE Primary Prophylaxis Treatments Will Promote Market Growth 13
2.3 Big Pharma Fuels Confidence in VTE Treatments via CV Label Expansions 14
2.4 Betrixaban to Acquire Critical Market Position by Addressing Unmet Needs 15
2.5 Opportunities Remain: The VTE Market Requires a Transformational Therapy 15
2.6 What Do Physicians Think? 16
3 Introduction 18
3.1 Catalyst 18
3.2 Related Reports 19
4 Disease Overview 20
4.1 Etiology and Pathophysiology 20
4.1.1 Etiology 20
4.1.2 Pathophysiology 20
4.2 Symptoms 21
4.3 Prognosis 22
4.4 Quality of Life 23
5 Epidemiology 24
5.1 Disease Background 24
5.2 Risk Factors and Comorbidities 25
5.3 Global and Historical Trends 26
5.4 Forecast Methodology 29
5.4.1 Sources 29
5.4.2 Forecast Assumptions and Methods 32
5.5 Epidemiological Forecast for VTE (2016-2026) 45
5.5.1 Diagnosed Incident Cases of Pulmonary Embolism 45
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1930314-pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2026

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

$3.8 Million Awarded to Researchers at University of Utah Health and Intermountain Healthcare

National Cancer Institute Grant Funds Advanced Cancer Screening Tool

SALT LAKE CITY, UTAH, USA, August 30, 2017 /EINPresswire.com/ — Researchers from the University of Utah Health, Intermountain Healthcare, and Huntsman Cancer Institute received a grant for $3.8 Million from the National Cancer Institute to develop an advanced cancer screening tool. The new tool will couple electronic health record technologies with advanced clinical decision support (CDS) tools to screen for several types of cancer and identify and manage high risk patients within primary care settings and the broader care delivery system.

“It is crucial that primary care physicians who are the frontline of care identify patients who are at high risk of developing cancer,” says grant co-investigator Scott Narus, PhD, Medical Informatics Director and Chief Clinical Systems Architect for Intermountain Healthcare. “Early diagnosis and screening of cancer greatly increases the chances for successful treatment.”

Increased scientific evidence supports individualizing cancer screening based on risk to better predict probabilities of cancer development. Informatics researchers are challenged by significant barriers to implementation of an effective clinical decision support tool because:

· Some electronic health record (EHR) systems have limited clinical decision support capabilities
· There is minimal sharing of clinical decision support rules among healthcare organizations
· Existing clinical decision support systems rely on closed architectures

U of U Health, Intermountain, and Huntsman Cancer institute researchers are determined to meet these challenges because there is a critical need for EHR-agnostic clinical decision support platforms that enable sharing across healthcare organizations.

“The goal of the CDS project is to enable a standards-based and scalable CDS platform for individualized cancer screening to be used across healthcare organizations,” say Principal Investigators Guilherme Del Fiol, MD, PhD and Kensaku Kawamoto, MD, PhD, both Assistant Professors of Biomedical Informatics at University of Utah Health. “To achieve this goal, our team of researchers will extend and solidify two well-established open source CDS Web services based on rule logic (OpenCDS) and information retrieval (OpenInfobutton).”

Working with primary care physicians, oncologists, and genetic counselors, researchers will develop CDS algorithms and interventions to support individualized screening of breast and colorectal cancer using two modalities:

1. Automatic detection of patients at high risk for breast and colorectal cancer according to national cancer guidelines;
2. Individualized evidence for providers and patients to better understand risk-appropriate screening strategies.

“With the collaboration between the University of Utah and Intermountain Healthcare, and the support of the National Cancer Institute, we have the potential to produce a CDS platform that has significant impact on individualizing cancer screening according to the best available evidence,” says Dr. Narus. “Our aim is to improve patient care and outcomes through evidence-based medicine.”

With consultation from Intermountain, University of Utah Health will be responsible for developing the CDS platform and workflows and demonstrating it in their care delivery system. Intermountain will then evaluate the solution against Intermountain’s care delivery system to show that the application and workflow are transferable to another organization and EHR.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

The Pacific Meso Center Receives $100,000 Towards the Anonymous $1 Million Challenge Pledge to Help Fight Mesothelioma

LOS ANGELES, CA, U.S., August 30, 2017 /EINPresswire.com/ — The Pacific Mesothelioma Center (PMC), a division of the Pacific Heart, Lung & Blood Institute (PHLBI), is pleased to announce a generous $100,000 gift from Roger G. Worthington, of the law office Worthington & Caron P.C. This donation, made in response to the anonymous $1 million challenge grant the PMC recently received, will be used to further the PMC’s ground-breaking research on malignant pleural mesothelioma, an asbestos-related cancer affecting the lining of the chest.

The gift will be used in support of PHLBI’s two new scientists – Dr. Masahide Tone and Dr. Yukiko Tone. Both scientists have worked at Cambridge University, Oxford University, University of Pennsylvania and Cedars Sinai Medical Center. They will work on novel immunotherapies for mesothelioma. Immunotherapy is an exciting and promising cancer treatment that uses the body’s immune system to fight cancer. It is the PMC’s firm belief that the future of mesothelioma treatment will involve combination therapy, including surgery, radiation, chemotherapy and immunotherapy. Further, rational combinations of various immunotherapies combined with traditional cancer therapies, holds the greatest promise for real progress in the treatment of mesothelioma and other cancers.

Roger Worthington is a long-time advocate for mesothelioma research. In 2005, in honor of his father Punch Worthington, Ph.D., Roger helped establish the David “Punch” Worthington Lab at the David Geffen School of Medicine at the UCLA Medical Center in Los Angeles. The Punch Worthington Lab. is the home of innovative research on novel strategies for the treatment of mesothelioma, lung cancer and other occupational cancers. Sadly, his father passed away in 2006 from lung-cancer caused by asbestosis.

"We certainly are pleased to provide PMC with additional funds towards the anonymous $1 million matching gift that the institute recently received and I encourage others to donate, no matter how small”, said Roger Worthington, long-term supporter of the PMC and principal of the Law Office of Worthington and Caron PC. “These funds will enable the PMC to continue their great work on mesenchymal stem cells with their groundbreaking research which holds immense potential to lead to effective treatments not only for mesothelioma but perhaps for many other cancers as well.”

“We are very fortunate to have the continued support of Mr. Worthington,” Dr. Cameron said. “We are tremendously indebted to him and to all those who contribute to PHLBI. This money will allow us to accelerate our search for novel therapies to improve both the longevity and the quality of life of those battling mesothelioma, lung cancer and other diseases of the chest."

Dr. Cameron is a pioneer in the field of mesothelioma, Director of the Comprehensive Mesothelioma Program at UCLA, Professor of Surgery at UCLA and Chief of Thoracic Surgery at the West LA Veterans Affairs Medical Center. He is also one of the PMC’s Scientific Advisors.

Matching gifts can be made either by mail or online, at http://www.phlbi.org/about/get-involved/donate/.

About The Pacific Mesothelioma Center: Established in 2002, The PHLBI is a 501(c) (3) non-profit institution. The PMC, a division of the PHLBI, is focused on the treatment and prevention of malignant pleural mesothelioma. The PMC serves a growing number of mesothelioma victims by supporting the nation’s first-of-its-kind research lab which provides laboratory-to-the bedside research that improves mesothelioma victims’ lives and longevity.

Clare Cameron
The Pacific Mesothelioma Center
310-478-4678
email us here


Source: EIN Presswire

3D Printing Medical Devices Market worth 1.88 Bn USD by 2022

3D Printing Medical Devices

3D Printing Medical Devices

New market study launched by ASDReports.com

AMSTERDAM, NETHERLANDS, August 30, 2017 /EINPresswire.com/ — The report, now available on ASDReports, "3D Printing Medical Devices Market by Component (3D Printers, 3D Bioprinters, Material (Plastic, Metal, Ceramic), Software & Services), Technology (EBM, LBM, Photopolymerization, 3DP, and DD), Product Type (Prosthetics, Implant) – Global Forecast to 2022", The global 3D printing medical devices market is expected to reach USD 1.88 Billion by 2022 from USD 0.84 Billion in 2017, at CAGR of 17.5% from 2017 to 2022. Key factors such technological advancements, increasing public-private funding, and growing applications in the healthcare industry are the major factors driving the growth of the 3D printing medical devices market across the globe.

By component, the software & services segment is expected to hold the largest market share in 2017
On the basis of component, the global 3D printing medical devices market is segmented into three broad categories, namely, equipment, materials, and software & services. The software & services market is estimated to command the largest share of the global 3D printing medical devices market in 2017. Increasing development of advanced software solutions to manufacture high-quality 3D-printed medical products is the key factor driving the growth of the services and software segment.

By technology, the photopolymerization segment projected to account for the largest share in 2017
Based on technology, the market is segmented into suture 3D printing medical devices, electron beam melting (EBM), laser beam melting (LBM), photopolymerization, droplet deposition or extrusion-based technologies, PolyJet technology, and three-dimensional printing (3DP) or adhesion bonding or binder jetting. The photopolymerization segment is expected to hold the largest share of the 3D printing medical devices market in 2017. This is attributed to the widespread application of this technology across the medical industry, for manufacturing surgical guides (orthopedic, dental, and CMF guides), prosthetics and implants, porous scaffolds, and dental restorations.

By type, the surgical guides segment is expected to hold the largest market share in 2017
On the basis of type, the 3D-printed medical products market is segmented into surgical guides, surgical instruments, prosthetics & implants, and tissue engineering products. The surgical guides segment is expected to account for the largest share of the 3D printing medical devices market in 2017. 3D printing surgical guides as a part of surgical planning can significantly improve the precision of implant placement and provide accurate implant restorations. Due to this, the demand for precise and affordable guides is increasing; this is the key factor driving the growth of this market segment.

North America is expected to dominate the market in 2017
As of 2017, North America held the largest share of the global 3D printing medical devices market, followed by Europe. Its large share is attributed to the rising demand for organ transplants across this region. The presence of a highly developed healthcare infrastructure and significant government & private investments to develop advanced 3D printing technologies & applications are the key factors responsible for the large share of this regional segment. Additionally, conferences and trade are also supporting the growth of the 3D printing medical devices market in North America.

The key players in the global 3D printing medical devices market are Stratasys, Ltd. (Israel & U.S.), 3D Systems Corporation (U.S.), EnvisionTEC GmbH (Germany), Materialise NV (Belgium), EOS GmbH (Germany), Arcam AB (Sweden), Concept Laser GmbH (Germany), Renishaw plc (U.K.), Prodways Group (France), and 3T RPD Ltd. (U.K.).

More reports on 3D printing can be found on ASDReports. Find more Automation & Process Control reports on ASDReports as well.

Stefan Koopman
ASDReports
+31204869620
email us here


Source: EIN Presswire

Breast Cancer Therapeutics Development and Professional Review Analysis 2017

Breast Cancer Pharmaceutical and Healthcare Pipeline Review H2

PUNE, INDIA, August 30, 2017 /EINPresswire.com/ — Summary
Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/839589-breast-cancer-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.
Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 19
Breast Cancer Overview 20
Therapeutics Development 21
Breast Cancer – Therapeutics under Development by Companies 23
Breast Cancer – Therapeutics under Investigation by Universities/Institutes 66
Breast Cancer – Pipeline Products Glance 75
Breast Cancer – Products under Development by Companies 79
Breast Cancer – Products under Investigation by Universities/Institutes 145
Breast Cancer – Companies Involved in Therapeutics Development 160
Breast Cancer – Therapeutics Assessment 617
Drug Profiles 713
Breast Cancer – Dormant Projects 2934
Breast Cancer – Discontinued Products 3000
Breast Cancer – Product Development Milestones 3013
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/839589-breast-cancer-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
email us here


Source: EIN Presswire

Inflammatory Bowel Diseases (IBD) Therapeutic and Drug Pipeline Review H2

Inflammatory Bowel Diseases (IBD) – Analysis by stage of development, drug target, mechanism of action, route of administration and molecule type

PUNE, INDIA, August 30, 2017 /EINPresswire.com/ — Pune, India, 30th August 2017: WiseGuyReports announced addition of new report, titled “Irritable Bowel Syndrome – Pipeline Review, H2 2016”.

Summary
Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/752817-irritable-bowel-syndrome-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.Irritable Bowel Syndrome.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome – Overview 11
Irritable Bowel Syndrome – Therapeutics under Development by Companies 12
Irritable Bowel Syndrome – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome – Products under Development by Companies 17
Irritable Bowel Syndrome – Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
Alfa Wassermann S.p.A 21
Ardelyx, Inc. 22
Astellas Pharma Inc. 23
CJ HealthCare Corp. 24
Dong-A Socio Holdings Co. Ltd. 25
Enterome Bioscience SA 26
GlaxoSmithKline Plc 27
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
email us here


Source: EIN Presswire

Rhino-Conjunctivitis Therapeutics Development and Professional Review Analysis 2017

Rhino-Conjunctivitis Therapeutic and Drug Pipeline Review H1

PUNE, INDIA, August 30, 2017 /EINPresswire.com/ — Pune, India, 18 July 2017: WiseGuyReports announced addition of new report, titled “Rhino-Conjunctivitis – Pipeline Review, H1 2017”.

Summary
Rhinitis is characterized by one or several of the following symptoms: nasal congestion, runny nose, post-nasal drip, sneezing, red eyes (conjunctivitis), and itching of the nose or eyes. It may be allergic or non-allergic. It is important to enact environmental control measures to avoid the allergens that are causing the problem.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1555346-rhino-conjunctivitis-pipeline-review-h1-2017

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Rhino-Conjunctivitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 7, 8, 1 and 1 respectively.

Rhino-Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Rhino-Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Rhino-Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis (Ophthalmology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Rhino-Conjunctivitis (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Rhino-Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rhino-Conjunctivitis – Overview
Rhino-Conjunctivitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Rhino-Conjunctivitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhino-Conjunctivitis – Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma GmbH & Co KG
Allergy Therapeutics Plc
ASIT Biotech SA
Astellas Pharma Inc
Bial – Portela & Ca SA
Faes Farma SA
Griffin Discoveries BV
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1555346-rhino-conjunctivitis-pipeline-review-h1-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
Wise Guy Consultants Pvt. Ltd.
+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)
email us here


Source: EIN Presswire